New hepatitis C treatment approved

The  TGA has approved a new hepatitis C treatment, Gilead Sciences, Australia New Zealand, today announced. Harvoni (ledipasvir/ sofosbuvir) is the first daily single tablet regimen for the treatment of genotype one chronic hepatitis C (HCV) in adults. In clinical trials, it was shown that up to 99% of patients with HCV genotype one taking